Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $2.7 million.

  • Exagen's Gains from Investment Securities changed N/A to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 122067.8%. This contributed to the annual value of $490000.0 for FY2024, which is 2969.87% down from last year.
  • Exagen's Gains from Investment Securities amounted to $2.7 million in Q3 2025.
  • In the past 5 years, Exagen's Gains from Investment Securities registered a high of $2.7 million during Q3 2025, and its lowest value of $30000.0 during Q2 2022.
  • Its 5-year average for Gains from Investment Securities is $411500.0, with a median of $184500.0 in 2023.
  • In the last 5 years, Exagen's Gains from Investment Securities skyrocketed by 1720000.0% in 2021 and then plummeted by 9460.43% in 2022.
  • Quarter analysis of 5 years shows Exagen's Gains from Investment Securities stood at $171000.0 in 2021, then plummeted by 81.29% to $32000.0 in 2022, then surged by 387.5% to $156000.0 in 2023, then dropped by 28.85% to $111000.0 in 2024, then skyrocketed by 2305.41% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $438000.0 for Q2 2025, and $677000.0 during Q1 2025.